 |
|
 |
 |

Home > Company Index > Drugs > Drugs - Generic > IVAX Corporation
 |
IVAX Corporation |
 |
 |
 |
PROFILE |
 |
IVAX's fortunes are waxing again. After selling its chemicals and cosmetics lines, IVAX is focusing on developing specialty generic pharmaceuticals, respiratory drugs, and cancer treatments. The company's generic products (some 50% of sales) include almost 60 prescription drugs (sold under the Zenith Goldline and Goldline brands) and about 280 drugs and vitamins sold over-the-counter. IVAX's proprietary drugs include its cancer treatment Paxene, asthma inhaler Easi-Breathe, and urinary bladder disease treatment Elmiron. The company also makes veterinary drugs. IVAX merged its diagnostics unit with office products and services provider b2bstores.com; the new company, IVAX Diagnostics, is about 70% controlled by IVAX.
COMPETITION |
 |
Aventis (AVE)
Bristol-Myers Squibb Company (BMY)
GlaxoSmithKline plc (GSK)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 793.40
1-Yr. Sales Growth: 20.9%
Employees: 5,800
Revenue per employee: $136,793.10
KEY PEOPLE |
 |
Phillip Frost
CEO
Thomas E. Beier
CFO
CONTACT INFO |
 |
4400 Biscayne Blvd.
Miami, FL 33137
US
Phone: 305-575-6000
Fax: -
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |